DBV Technologies | DBVT - Current Assets


DBV Technologies reported $201.9M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amarin USD 602.76M 23.26M Jun/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
DBV Technologies USD 201.9M 44.8M Jun/2026
Galectin Therapeutics USD 27.29M 1.83M Jun/2024
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Insmed USD 1.61B 181.04M Mar/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
United Therapeutics USD 3.48B 611.7M Jun/2026